LncRNA LINC00665通过miR-9-5p调节ATF1表达促进甲状腺乳头状癌进展

被引:0
|
作者
赵爱兵 [1 ]
马丽华 [2 ]
窦国章 [3 ]
吴长明 [1 ]
吴双红 [3 ]
李子安 [4 ]
张东伟 [5 ]
机构
[1] 唐山工人医院胃肠外二科
[2] 唐山工人医院乳腺外科
[3] 唐山工人医院创伤科
[4] 唐山工人医院胃肠外一科
[5] 唐山工人医院烧伤整形一科
关键词
长链非编码RNA LINC00665; miR-9-5p; 转录激活因子1; 甲状腺乳头状癌; 增殖;
D O I
暂无
中图分类号
R736.1 [甲状腺肿瘤];
学科分类号
摘要
目的 探究LncRNA LINC00665通过miR-9-5p调节转录激活因子(ATF)1表达,促进甲状腺乳头状癌(PTC)的进展。方法 收集手术切除的PTC组织及癌旁组织80例,qRT-聚合酶链反应(PCR)分析PTC组织及癌旁组织、PTC细胞系中LINC00665与miR-9-5p的相对表达,分析LINC00665与miR-9-5p在PTC中的相关性。B-CPAP细胞分为对照组、阴性对照组、shLINC00665组和shLINC00665+miR-9-5p-inhibitor组,进行对应转染。Target Scan Human预测和双荧光素酶报告基因检测分析LINC00665、ATF1和miR-9-5p的靶向调节关系。CCK-8法检测细胞增殖能力,Transwell检测细胞迁移和侵袭能力,流式检测细胞凋亡,Western印迹检测PTC及癌旁组织ATF1和细胞ATF1、凝血酶敏感蛋白(TSP)-1、B细胞淋巴瘤(Bcl)-2、Bcl-2相关X蛋白(Bax)表达水平,体内异种移植实验检测肿瘤发展能力,免疫组化检测肿瘤ATF1表达。结果 与癌旁组织相比,PTC组织中LncRNA LINC00665、ATF1表达量显著升高,LncRNA LINC00665与miR-9-5p水平呈显著负相关(P<0.05)。与Nthy-ori3-1相比,TPC-1、KTC-1、B-CPAP、HTori-3的LINC00665表达量均显著升高,miR-9-5p表达量均显著降低(P<0.05)。LINC00665与miR-9-5p、miR-9-5p与ATF1存在结合位点,LINC00665靶向抑制miR-9-5p, miR-9-5p靶向抑制ATF1。与对照组相比,shLINC00665组细胞增殖活性、迁移与侵袭能力、Bcl-2表达量、皮下肿瘤生长速度与ATF1表达量显著降低,凋亡率、TSP-1、Bax表达量显著升高(P<0.05);与shLINC00665组相比,shLINC00665+miR-9-5p-inhibitor组细胞增殖活性、迁移与侵袭能力、Bcl-2表达量、皮下肿瘤生长速度与ATF1表达量显著提升,凋亡率、TSP-1、Bax表达量显著下降(P<0.05)。结论 LncRNA LINC00665能够靶向调控miR-9-5p表达,降低miR-9-5p对ATF1的抑制,促进PTC发展。
引用
收藏
页码:1145 / 1151
页数:7
相关论文
共 22 条
  • [11] Circular RNA expression and association with the clinicopathological characteristics in papillary thyroid carcinoma
    Guo, Dan
    Li, Fangyuan
    Zhao, Xiaoxiao
    Long, Bo
    Zhang, Sumei
    Wang, Anqi
    Cao, Dingyan
    Sun, Jian
    Li, Binglu
    [J]. ONCOLOGY REPORTS, 2020, 44 (02) : 519 - 532
  • [12] miR-9-5p Suppresses Malignant Biological Behaviors of Human Gastric Cancer Cells by Negative Regulation of TNFAIP8L3
    Fan, Yanyun
    Shi, Ying
    Lin, Zhenhe
    Huang, Xiaoxiao
    Li, Jinying
    Huang, Wei
    Shen, Dongyan
    Zhuang, Guohong
    Liu, Wenming
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (10) : 2823 - 2829
  • [13] Preoperative Staging of Differentiated Thyroid Carcinomas: Comparison of USG and CT with Intraoperative Findings and Histopathology
    Jainulabdeen, Thasneem
    Ramaswamy, Balakrishnan
    Devaraja, K.
    Paruthikunnan, Samir M.
    Bhandarkar, Ajay M.
    [J]. INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2019, 71 (03) : 327 - 333
  • [14] Emerging roles of lncRNA in cancer and therapeutic opportunities
    Jiang, Ming-Chun
    Ni, Jiao-Jiao
    Cui, Wen-Yu
    Wang, Bo-Ya
    Zhuo, Wei
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (07): : 1354 - 1366
  • [15] Verification of expressions of lncRNA FOXCUT in gastric adenocarcinoma patients and its effects on cell biological function based on TCGA database..[J].Zhao D-L;Shen G.European review for medical and pharmacological sciences.2019, 14
  • [16] Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma.[J].Changjiao Yan;Meiling Huang;Xin Li;Ting Wang;Rui Ling.Endocrine Connections.2019, 7
  • [17] The function of miRNA‑153 against isoflurane‑induced neurotoxicity via Nrf2/ARE cytoprotection..[J].Shao Dong;Wu Zhouquan;Bai Shuying;Fu Guowei;Zou Zhiqing.Molecular medicine reports.2019, 5
  • [18] The human ATF1 rs11169571 polymorphism associated with risk of nasopharyngeal carcinoma in Southern Chinese populations
    Peng, Shutang
    Huang, Guo-Liang
    Xu, Nansong
    Lu, Yan
    Zeng, Liuyan
    Li, Xin
    Luo, Shengqun
    Lyu, Xiaoming
    Jiang, Qiang
    Li, Tong
    He, Zhiwei
    [J]. CANCER MEDICINE, 2019, 8 (04): : 1893 - 1898
  • [19] LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis
    Wu, Meng
    Huang, Yawei
    Chen, Tongchang
    Wang, Weichao
    Yang, Shiguang
    Ye, Zhenfeng
    Xi, Xiaoqing
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (01) : 29 - 38
  • [20] lncRNA DGCR5 acts as a tumor suppressor in papillary thyroid carcinoma via sequestering miR-2861
    Chen, Fukun
    Yin, Shuting
    Zhu, Jialun
    Liu, Pengjie
    Yang, Chuanzhou
    Feng, Zhiping
    Deng, Zhiyong
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (01) : 895 - 900